Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

Written by Customer Service on May 26, 2022. Posted in Public Companies.

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the American Society of Clinical Oncology Annual Meeting being held in Chicago, Illinois and virtually from June 3 through June 7, 2022. The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC). “There is a significant need for new treatment options for patients with NMIBC, one of the most recurrent and difficult to treat cancers,” said Jathin Bandari, M.D., Chief Medical Officer of Protara Therapeutics. “Based on its mechanism of action,...

Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models

Written by Customer Service on May 26, 2022. Posted in Public Companies.

In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitors NEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of an abstract at the American Society of Clinical Oncology (ASCO) Annual Meeting. Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how narazaciclib’s inhibitory profile differentiates it from the FDA-approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib. Key data and conclusions from the abstract include: Narazaciclib, abemaciclib, palbociclib, and ribociclib each have...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting

Written by Customer Service on May 26, 2022. Posted in Public Companies.

Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentation of a poster entitled, “nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program” at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held online and in person from June 3-7 in Chicago, IL. The data represent exploratory biomarker results reported from the final analysis of...

Fanhua Announces Distribution of CNFinance Shares

Written by Customer Service on May 26, 2022. Posted in Public Companies.

GUANGZHOU, China, May 26, 2022 (GLOBE NEWSWIRE) — Fanhua Inc. (the “Company” or “Fanhua”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that its board of directors has authorized and approved the Company’s distribution of shares of CNFinance Holdings Limited (“CNFinance”) to the Company’s shareholders on a pro rata basis. CNFinance is a leading home equity loan service provider in China and its ADSs are currently traded on the New York Stock Exchange (NYSE: CNF). Based on the number of ordinary shares of Fanhua outstanding as of May 26, 2022, the Company estimates that its shareholders will receive approximately 4.71 CNFinance ordinary shares for each 20 Fanhua ordinary shares, or 0.2355 CNFinance ADSs for each Fanhua ADS, held as of the Record Date (as defined below). The CNFinance...

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on May 26, 2022. Posted in Public Companies.

Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and activity observed in multiple tumor types Updated data from ongoing Phase 1/2 PYNNACLE trial to be presented during oral presentation on June 7 Company to host an investor event on June 7 to review data presented CRANBURY, N.J., May 26, 2022 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the online publication of the abstract for its lead program, PC14586, accepted as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting being...

Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on May 26, 2022. Posted in Public Companies.

WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of Arbutus’ oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022. Details for the abstract selected for publication are as follows: Title: Pre-clinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors Abstract Number: e14558 Authors: Emily P Thi, Andrew G Cole, Gavin Heffernan, Christina L Iott, Seyma Ozturk, Sharie C Ganchua, Dan Nguyen, Ingrid Graves,...

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Written by Customer Service on May 26, 2022. Posted in Public Companies.

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with SNK01 autologous natural killer cells in patients with advanced EGFR-expressing solid tumors HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that three abstracts of clinical trial designs of its AFM24 innate cell engager (ICE®) have been published and will be presented at the American...

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Written by Customer Service on May 26, 2022. Posted in Public Companies.

Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable Diseases (SD) as of the February 10, 2022 abstract deadline Additional data to be presented during the poster presentation at ASCO 2022 Etigilimab safe and well tolerated, no new safety signals LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical...

Galane Gold Ltd. Releases Financial and Operating Results for Q1

Written by Customer Service on May 26, 2022. Posted in Earnings Releases And Operating Results.

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) — Galane Gold Ltd. (“Galane Gold” or the Company”) (TSX-V: GG; OTCQB: GGGOF) is pleased to announce the release of its financial results for the three months ended March 31, 2022. A copy of the unaudited condensed consolidated interim financial statements for the three months ended March 31, 2022 prepared in accordance with International Financial Reporting Standards and the corresponding Management’s Discussion and Analysis are available under the Company’s profile on www.sedar.com. All references to “$” in this press release refer to United States dollars. First Quarter 2022 Highlights Produced 2,286 tonnes of concentrate containing 3,143 ounces of gold (Q4 2021 – 2,662 tonnes of concentrate containing 2,440 ounces of gold) at Galaxy. 2,357 payable ounces of gold produced at an operating...

Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting

Written by Customer Service on May 26, 2022. Posted in Public Companies.

RECIST responses observed in IO-refractory patients and in IO-resistant indications 30% ORR in patients treated at the two highest TPST-1120 doses in combination with nivolumab (3/10); 20% ORR in all evaluable combination patients (3/15) 53% DCR in monotherapy patients (10/19) Responses observed in patients with heavily pre-treated renal cell carcinoma (ORR 50%, 2/4) and cholangiocarcinoma, including patients with cancer that were previously refractory to anti-PD-1 treatment TPST-1120 was well-tolerated both as a monotherapy and in combination with nivolumab Randomized global Phase 1b/2 study is ongoing in previously untreated patients with hepatocellular carcinoma Investor event and webcast featuring key opinion leaders scheduled for Sunday, June 5, at ASCO SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) — Tempest...

Day: May 26, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice